Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

References

• Jemal A, Siegel R, Xu J, . Cancer statistics, 2010. CA Cancer J Clin2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Paltiel O, Rubinstein C, Or R, . Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant2003;31:565–569.
   PubMed Web of Science ®Google Scholar
• Woehrer S, Hejna M, Skrabs C, . Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B cell lymphoma. Oncology2005;69: 499–502.
   PubMed Web of Science ®Google Scholar
• Stamenkovic I, Clark EA, Seed B.A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J1989;8:1403–1410.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J.Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol1997;9:330–337.
   PubMed Web of Science ®Google Scholar
• Gruss HJ, Dower SK.Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood1995;85:3378–3404.
   PubMed Web of Science ®Google Scholar
• Tong AW, Stone MJ.Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther2003;10:1–13.
   PubMed Web of Science ®Google Scholar
• Law CL, Gordon KA, Collier J, . Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res2005;65:8331–8338.
   PubMed Web of Science ®Google Scholar
• Lewis TS, Sutherland MSK, Jonas M, . The humanized anti-CD40 antibody, SGN-40, promotes apoptosis signaling and is effective in combination with standard therapies in lymphoma xenograft models. Blood2006;108(Suppl. 1): Abstract 2499.
   Google Scholar
• Dacetuzumab investigators's brochure; version 6, 12 March 2009. Seattle, WA: Seattle Genetics, Inc.; 2009.
   Google Scholar
• Hussein MA, Berenson JR, Niesvizky R, . A phase I humanized anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma. Blood2005;106(Suppl. 1): Abstract 2572.
   Google Scholar
• Advani R, Forero-Torres A, Furman RR, . Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol2009;27:4371–4377.
   PubMed Web of Science ®Google Scholar
• Advani R, De Vos S, Ansell SM, . A phase 2 clinical trial of SGN-40 monotherapy in relapsed diffuse large B-cell lymphoma. Blood2008;112(Suppl. 1): Abstract 1000.
   Google Scholar
• Barton-Burke M.Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs1999;22:176–183.
   PubMed Web of Science ®Google Scholar
• Fossa A, Santoro A, Hiddemann W, . Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol1999;17:3786–3792.
   PubMed Web of Science ®Google Scholar
• Jajeh A, Hadad L, Zalzaleh G, . Gemcitabine as single agent in the treatment of relapsed and refractory Hodgkin and non-Hodgkin lymphoma. Blood2003;102(Suppl. 1): Abstract 4861.
   Google Scholar
• Emmanouilides C, Jazirehi AR, Bonavida B.Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm2002;17:621–630.
   PubMed Web of Science ®Google Scholar
• Wenger C, Stern M, Herrmann R, . Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?Leuk Lymphoma2005;46:71–75.
   PubMed Web of Science ®Google Scholar
• Lopez A, Gutierrez A, Palacios A, . GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol2008;80:127–32.
   PubMed Web of Science ®Google Scholar
• Lewis TS, McCormick RS, Stone IJ, . Dacetuzumab (SGN-40), a humanized anti-CD40 monoclonal antibody, has chemosensitization activity and improves gemcitabine efficacy in NHL xenograft models. Paper presented at AACR Annual Meeting. April2009. Denver, CO. Abstract 3243.
   Google Scholar
• Advani R, Forero-Torres A, Furman RR, . SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin lymphoma: final results of a phase I dose-escalation study. Ann Oncol2008;19(Suppl. 2): Abstract 099.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Seyfarth B, Josting A, Dreyling M, . Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin's disease. Br J Haematol2006;133:3–18.
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Bell DR, Millward MJ, . Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer1997;80:286–291.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeck A, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Gnaoui TE, Dupuis J, Belhadj K, . Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol2007;18:1363–1368.
   PubMed Web of Science ®Google Scholar
• Corazelli G, Capobianco G, Arcamone M, . Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol2009;64:907–916.
   PubMed Web of Science ®Google Scholar
• Burington B, Yue P, Shi X, . CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med2011;3:1–12.
   Google Scholar